Phase 3 Efficacy Study of LNZ100 & LNZ101 for the Treatment of Presbyopia

Completed · Phase 3

Conditions studied: Presbyopia, Near Vision, Refractive Error, Eye Diseases

In brief

Phase 3 Efficacy Study to evaluate the Safety and Efficacy of LNZ100 \& LNZ101 for the Treatment of Presbyopia

Key facts

Study ID

NCT05728944

Run by

LENZ Therapeutics, Inc

People needed

229

Starts

2023-03-06

Expected to finish

2024-01-24

Last updated by the study team

2026-02-25

Who can join

Age: 45 and older, up to 75. Sex: any. Healthy volunteers: accepted.

Where it is running

• Site #209 — Dothan, Alabama, United States
• Site #216 — Scottsdale, Arizona, United States
• Site #220 — Glendale, California, United States
• Site #214 — La Jolla, California, United States
• Site #203 — Newport Beach, California, United States
• Site #204 — Danbury, Connecticut, United States
• Site #205 — Crystal River, Florida, United States
• Site #218 — Northbrook, Illinois, United States
• Site #211 — Louisville, Kentucky, United States
• Site #208 — St Louis, Missouri, United States
• Site #215 — Bozeman, Montana, United States
• Site #219 — Dover, New Jersey, United States
• Site #221 — Rochester, New York, United States
• Site #212 — West Fargo, North Dakota, United States
• Site #207 — Powell, Ohio, United States
• Site #213 — Eugene, Oregon, United States
• Site #217 — Warwick, Rhode Island, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.